Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis, Multidrug-Resistant | 13 | 2023 | 912 | 1.060 |
Why?
|
| Antitubercular Agents | 15 | 2018 | 1320 | 0.990 |
Why?
|
| Latent Tuberculosis | 1 | 2021 | 225 | 0.640 |
Why?
|
| Mycobacterium tuberculosis | 10 | 2018 | 1832 | 0.580 |
Why?
|
| Clonorchis sinensis | 1 | 2010 | 2 | 0.390 |
Why?
|
| Tuberculosis, Pulmonary | 5 | 2021 | 810 | 0.350 |
Why?
|
| Tuberculosis | 5 | 2023 | 1912 | 0.350 |
Why?
|
| Heart Aneurysm | 1 | 2010 | 120 | 0.350 |
Why?
|
| Infarction | 1 | 2010 | 244 | 0.320 |
Why?
|
| Chagas Disease | 1 | 2010 | 166 | 0.310 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2010 | 369 | 0.300 |
Why?
|
| Ascariasis | 1 | 2006 | 12 | 0.280 |
Why?
|
| Ascaris lumbricoides | 1 | 2006 | 11 | 0.280 |
Why?
|
| Cholangitis | 1 | 2006 | 108 | 0.260 |
Why?
|
| Bile Ducts | 1 | 2006 | 284 | 0.250 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2023 | 2232 | 0.240 |
Why?
|
| HIV Infections | 8 | 2023 | 16715 | 0.240 |
Why?
|
| Liver | 2 | 2010 | 7475 | 0.220 |
Why?
|
| Tissue and Organ Procurement | 1 | 2010 | 896 | 0.210 |
Why?
|
| Anthozoa | 1 | 2021 | 62 | 0.200 |
Why?
|
| Tuberculosis, Spinal | 2 | 2017 | 16 | 0.190 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2019 | 14 | 0.180 |
Why?
|
| Liver Transplantation | 1 | 2010 | 2119 | 0.170 |
Why?
|
| Awards and Prizes | 1 | 2023 | 375 | 0.170 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2019 | 82 | 0.160 |
Why?
|
| Tuberculosis, Male Genital | 1 | 2018 | 6 | 0.160 |
Why?
|
| Orchitis | 1 | 2018 | 35 | 0.160 |
Why?
|
| Epididymitis | 1 | 2018 | 37 | 0.160 |
Why?
|
| Tuberculosis, Osteoarticular | 1 | 2017 | 26 | 0.150 |
Why?
|
| Immunomodulation | 1 | 2021 | 541 | 0.150 |
Why?
|
| Tuberculosis, Urogenital | 1 | 2016 | 9 | 0.150 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2010 | 657 | 0.150 |
Why?
|
| Edema | 2 | 2018 | 789 | 0.140 |
Why?
|
| Sputum | 3 | 2014 | 476 | 0.130 |
Why?
|
| Directly Observed Therapy | 3 | 2012 | 137 | 0.130 |
Why?
|
| Testis | 1 | 2018 | 804 | 0.120 |
Why?
|
| Diagnosis, Differential | 8 | 2019 | 12961 | 0.120 |
Why?
|
| Kidney | 1 | 2010 | 7184 | 0.120 |
Why?
|
| South Africa | 4 | 2014 | 1731 | 0.120 |
Why?
|
| Joint Diseases | 1 | 1998 | 479 | 0.120 |
Why?
|
| Endometrium | 1 | 2016 | 424 | 0.120 |
Why?
|
| Endemic Diseases | 1 | 2014 | 182 | 0.110 |
Why?
|
| Abdominal Pain | 2 | 2010 | 1064 | 0.100 |
Why?
|
| Clonorchiasis | 1 | 2010 | 4 | 0.100 |
Why?
|
| Meningitis, Viral | 1 | 2011 | 50 | 0.100 |
Why?
|
| Musculoskeletal Diseases | 1 | 2017 | 581 | 0.100 |
Why?
|
| Antiparasitic Agents | 1 | 2010 | 41 | 0.090 |
Why?
|
| Nifurtimox | 1 | 2010 | 13 | 0.090 |
Why?
|
| Infertility, Female | 1 | 2016 | 788 | 0.090 |
Why?
|
| Laboratories, Hospital | 1 | 2011 | 194 | 0.090 |
Why?
|
| Peru | 5 | 2012 | 881 | 0.090 |
Why?
|
| Trypanocidal Agents | 1 | 2010 | 38 | 0.090 |
Why?
|
| Flank Pain | 1 | 2010 | 43 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2009 | 2026 | 0.090 |
Why?
|
| Knee Joint | 1 | 1998 | 1680 | 0.090 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2010 | 71 | 0.090 |
Why?
|
| Humans | 38 | 2023 | 744366 | 0.080 |
Why?
|
| Tuberculosis, Central Nervous System | 1 | 2008 | 16 | 0.080 |
Why?
|
| Tuberculosis, Cutaneous | 1 | 2008 | 17 | 0.080 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 1 | 2008 | 92 | 0.080 |
Why?
|
| National Health Programs | 1 | 2011 | 445 | 0.080 |
Why?
|
| Herpes Simplex | 1 | 2011 | 470 | 0.080 |
Why?
|
| Models, Organizational | 1 | 2011 | 574 | 0.080 |
Why?
|
| Sarcoma | 1 | 1998 | 1897 | 0.070 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2011 | 567 | 0.070 |
Why?
|
| Radiography, Abdominal | 1 | 2010 | 537 | 0.070 |
Why?
|
| Hepatic Duct, Common | 1 | 2006 | 50 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 738 | 0.070 |
Why?
|
| Program Evaluation | 2 | 2011 | 2488 | 0.070 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2011 | 518 | 0.070 |
Why?
|
| Mass Screening | 1 | 2021 | 5253 | 0.070 |
Why?
|
| Cholecystitis | 1 | 2006 | 182 | 0.060 |
Why?
|
| Liver Function Tests | 1 | 2006 | 528 | 0.060 |
Why?
|
| Cholelithiasis | 1 | 2006 | 414 | 0.060 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 5135 | 0.060 |
Why?
|
| Medically Underserved Area | 1 | 2006 | 253 | 0.060 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2006 | 504 | 0.060 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 1410 | 0.060 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 941 | 0.050 |
Why?
|
| Cholestasis | 1 | 2006 | 378 | 0.050 |
Why?
|
| Hepatectomy | 1 | 2006 | 550 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3135 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3242 | 0.050 |
Why?
|
| Treatment Outcome | 8 | 2018 | 63107 | 0.050 |
Why?
|
| Lung | 2 | 2019 | 9857 | 0.050 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2004 | 255 | 0.050 |
Why?
|
| Drug Resistance, Multiple | 1 | 2003 | 252 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 3778 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2018 | 5984 | 0.050 |
Why?
|
| Risk Factors | 3 | 2021 | 72296 | 0.050 |
Why?
|
| Adult | 16 | 2020 | 214052 | 0.050 |
Why?
|
| Cough | 2 | 2019 | 555 | 0.050 |
Why?
|
| Rifampin | 1 | 2023 | 315 | 0.050 |
Why?
|
| Sarcoma, Kaposi | 1 | 2004 | 370 | 0.050 |
Why?
|
| Animals | 6 | 2021 | 168768 | 0.050 |
Why?
|
| Anti-Retroviral Agents | 1 | 2010 | 1714 | 0.050 |
Why?
|
| HIV | 1 | 2007 | 1604 | 0.050 |
Why?
|
| Dengue | 1 | 2003 | 256 | 0.040 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5321 | 0.040 |
Why?
|
| Elephantiasis, Filarial | 1 | 2019 | 29 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2021 | 323 | 0.040 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 2 | 2010 | 66 | 0.040 |
Why?
|
| Cardiomyopathy, Hypertrophic, Familial | 1 | 2019 | 66 | 0.040 |
Why?
|
| Health Policy | 1 | 2011 | 2661 | 0.040 |
Why?
|
| Brain Diseases | 1 | 2008 | 1563 | 0.040 |
Why?
|
| Developing Countries | 1 | 2011 | 2815 | 0.040 |
Why?
|
| Drug Monitoring | 2 | 2017 | 956 | 0.040 |
Why?
|
| Anti-HIV Agents | 3 | 2012 | 4255 | 0.040 |
Why?
|
| Internal Medicine | 1 | 2006 | 1009 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2010 | 35425 | 0.040 |
Why?
|
| Lung Diseases, Fungal | 1 | 2019 | 122 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2011 | 2304 | 0.040 |
Why?
|
| Testicular Diseases | 1 | 2018 | 71 | 0.040 |
Why?
|
| Poverty | 2 | 2008 | 2660 | 0.040 |
Why?
|
| Hepatitis C, Chronic | 1 | 2006 | 1031 | 0.040 |
Why?
|
| Decision Making | 1 | 2011 | 3888 | 0.040 |
Why?
|
| Female | 18 | 2023 | 380193 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2010 | 4397 | 0.040 |
Why?
|
| Male | 14 | 2020 | 350115 | 0.040 |
Why?
|
| Hemofiltration | 1 | 2017 | 57 | 0.040 |
Why?
|
| Hysterosalpingography | 1 | 2016 | 30 | 0.040 |
Why?
|
| Tenosynovitis | 1 | 2017 | 57 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2014 | 2560 | 0.030 |
Why?
|
| Fallopian Tubes | 1 | 2016 | 182 | 0.030 |
Why?
|
| Orchiectomy | 1 | 2018 | 474 | 0.030 |
Why?
|
| Synovial Membrane | 1 | 1998 | 507 | 0.030 |
Why?
|
| Educational Status | 1 | 2023 | 2540 | 0.030 |
Why?
|
| Nepal | 1 | 2016 | 295 | 0.030 |
Why?
|
| Fever | 1 | 2003 | 1616 | 0.030 |
Why?
|
| Proportional Hazards Models | 3 | 2015 | 12356 | 0.030 |
Why?
|
| Counseling | 1 | 2023 | 1523 | 0.030 |
Why?
|
| Schools | 1 | 2023 | 1433 | 0.030 |
Why?
|
| Eosinophilia | 1 | 2019 | 541 | 0.030 |
Why?
|
| Public Health | 1 | 2007 | 2602 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 7914 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 7282 | 0.030 |
Why?
|
| Granuloma | 1 | 2016 | 319 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 9274 | 0.030 |
Why?
|
| Ethiopia | 1 | 2015 | 495 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 441 | 0.030 |
Why?
|
| Back Pain | 1 | 2017 | 545 | 0.030 |
Why?
|
| Arthritis, Infectious | 1 | 2017 | 367 | 0.030 |
Why?
|
| Osteomyelitis | 1 | 2017 | 402 | 0.030 |
Why?
|
| Arthritis | 1 | 1998 | 661 | 0.030 |
Why?
|
| Time Factors | 5 | 2014 | 40075 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 1265 | 0.030 |
Why?
|
| Georgia (Republic) | 1 | 2011 | 41 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 7182 | 0.030 |
Why?
|
| Lesotho | 1 | 2011 | 70 | 0.020 |
Why?
|
| Middle Aged | 6 | 2020 | 213390 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2012 | 1872 | 0.020 |
Why?
|
| Integrin alpha4 | 1 | 2011 | 92 | 0.020 |
Why?
|
| Therapeutic Equipoise | 1 | 2010 | 28 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2020 | 1860 | 0.020 |
Why?
|
| Pregnancy | 4 | 2023 | 29144 | 0.020 |
Why?
|
| Russia | 1 | 2011 | 408 | 0.020 |
Why?
|
| Herpesvirus 3, Human | 1 | 2011 | 204 | 0.020 |
Why?
|
| Herpesvirus 2, Human | 1 | 2011 | 189 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 20130 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2011 | 438 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2021 | 9849 | 0.020 |
Why?
|
| Financing, Personal | 1 | 2011 | 308 | 0.020 |
Why?
|
| Fertilization in Vitro | 1 | 2016 | 1284 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2014 | 1461 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2017 | 1783 | 0.020 |
Why?
|
| Massachusetts | 1 | 2020 | 8662 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2008 | 211 | 0.020 |
Why?
|
| Child | 2 | 2012 | 77709 | 0.020 |
Why?
|
| Public Sector | 1 | 2007 | 265 | 0.020 |
Why?
|
| Retrospective Studies | 5 | 2014 | 77460 | 0.020 |
Why?
|
| Community Health Services | 1 | 2011 | 650 | 0.020 |
Why?
|
| Comorbidity | 1 | 2020 | 10388 | 0.020 |
Why?
|
| Urban Health | 1 | 2008 | 547 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2019 | 6442 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2011 | 686 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2006 | 5791 | 0.020 |
Why?
|
| Young Adult | 4 | 2015 | 56429 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2014 | 1178 | 0.020 |
Why?
|
| Program Development | 1 | 2011 | 1316 | 0.020 |
Why?
|
| Critical Illness | 1 | 2017 | 2670 | 0.020 |
Why?
|
| Health Plan Implementation | 1 | 2007 | 352 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 6755 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2009 | 1851 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2015 | 2063 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2013 | 6366 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 1504 | 0.010 |
Why?
|
| Sri Lanka | 1 | 2003 | 90 | 0.010 |
Why?
|
| Models, Educational | 1 | 2006 | 377 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2011 | 2617 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 4933 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2012 | 6459 | 0.010 |
Why?
|
| Dyspnea | 1 | 2009 | 1303 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2011 | 2616 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8385 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2011 | 5524 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2004 | 13104 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2011 | 2531 | 0.010 |
Why?
|
| Social Support | 1 | 2008 | 2118 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 6489 | 0.010 |
Why?
|
| Radiography | 1 | 2009 | 7023 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 15078 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2020 | 40559 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2011 | 3208 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2008 | 2708 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2003 | 1877 | 0.010 |
Why?
|
| Travel | 1 | 2003 | 788 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8642 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 3154 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 57776 | 0.010 |
Why?
|
| Curriculum | 1 | 2006 | 3605 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2009 | 25628 | 0.010 |
Why?
|
| Aged | 1 | 2020 | 163288 | 0.000 |
Why?
|
| Adolescent | 1 | 2009 | 85779 | 0.000 |
Why?
|
| United States | 1 | 2006 | 69872 | 0.000 |
Why?
|
Concepts
(214)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(89)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_